AF is the most common clinical arrhythmia, affecting at least 1-2% of the population.
Patients presenting with new onset AF to emergency departments can be managed in a number of different ways, depending on the clinical scenario. In general, either a rate control or rhythm control strategy is chosen. When an early rate control strategy is selected, the options are either electrical cardioversion under sedation or to use a pharmacological agent to facilitate chemical cardioversion.
The European Society of Cardiology 2016 guidelines recommend the use of flecainide, amiodarone, propafenone, ibutilide or vernakalant for pharmacological cardioversion, with the choice of agent guided by the presence of any underlying heart disease ( Figure 1) . 5 Vernakalant is an atrial-selective compound that rapidly blocks potassium and sodium ion channels in all phases of the atrial action potential. 6 Potassium currents that are expressed specifically in the atria and involved in atrial repolarisation are blocked before the secondary effect of sodium channels inhibition. Vernakalant is unique among antiarrhythmic drugs because its affinity for the activated sodium channel becomes greater as heart rate increases. 7 The pharmacological profile of vernakalant addresses many problems of other antifibrillatory drugs by selectively targeting ion channels that are expressed primarily in atrial cardiomyocytes. Blocking the rapidly activating potassium current accounts for only mild QT prolongation and this rapidly returns to baseline after cessation of the infusion. 8 
Safety Profile
The pharmacokinetic profile of vernakalant demonstrates rapid distribution with a short half-life, so therefore it is less likely to cause drugdrug interactions. 7 Vernakalant is metabolised by the liver with a half-life of about 3 hours and up to 8 hours in poor metabolisers. 9 Peak plasma concentrations are evident at the end of the 10-minute infusion but fall rapidly at the end of infusion. Vernakalant is contraindicated when:
• systolic blood pressure is <100 mmHg;
• severe aortic stenosis or heart failure (New York Heart Association
[NYHA] Class III and IV) is present;
• an acute coronary syndrome has occurred within the previous 30 days; or
• there is QT prolongation >440 msec.
Vernakalant should also be avoided when intravenous Class I and III antiarrhythmic drugs have been administered within the previous 4 hours. Prior to its administration, patients should be adequately hydrated with a normal potassium level.
Vernakalant is not recommended in patients with:
• left ventricular ejection fraction <35%;
• hypertrophic obstructive cardiomyopathy;
• restrictive cardiomyopathy or constrictive pericarditis;
• advanced hepatic impairment; or
• clinically meaningful valvular stenosis.
There is insufficient data relating to the administration of vernakalant with placebo or amiodarone. 7, 11 Serious adverse events related to medication administration was reported in 2.1% of people receiving vernakalant, compared to 0.3% of those receiving placebo. 11 Hypotension as a serious event was reported in 1.2% versus 0.3% in the placebo group and when this occurred in the first 2 hours it was most common in patients with heart failure. 11 Bradycardia was slightly more common in the vernakalant group, but rarely led to discontinuation of the drug. There was no significant effect on the ventricular rate during AF while receiving vernakalant and neither was there no excess in ventricular arrhythmias compared to placebo. Non-sustained ventricular arrhythmias were, however, more prevalent in the presence of heart failure and hence the cautionary use in this group (7.3% versus 1.6% in placebo at 2 hours).
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The most commonly reported side-effects are shown in Table 1 .
In the above pooled safety data, taste disturbance, sneezing, paraesthesia and nausea were most commonly reported; these are believed to be secondary to the effects on sodium channels in the central nervous system. An electrocardiogram in AF and another after cardioversion has taken place is also advisable.
One vial of vernakalant is sufficient for both infusions if needed, and if the infusion is well tolerated and can be given peripherally. A condensed version of the protocol for administration is shown in Figure 2 .
Clinical Trials
The efficacy of vernakalant was researched in a single dose finding trial, three randomised placebo-controlled phase III trials, one randomised active-controlled trial with amiodarone, and a phase IV open-label study ( Table 2) . [12] [13] [14] [15] [16] [17] [18] The ACT I and III trials showed vernakalant was significantly more effective than the placebo in converting AF of short duration (>3 hours to ≥7 days; 51.7% versus 4%; p<0.001; and 51.2% versus 3.6%; p<0.0001). 14,15 When compared to amiodarone, vernakalant was more effective in achieving cardioversion of short duration AF (3-48 hours) within 90 minutes of drug infusion. 12 The median time to conversion was 11 and 8 minutes, respectively, in the ACT I and III studies and rates of conversion was highest when the AF was of a duration ≤48 hours (62.1% versus 4.9%; p<0.001). The ACT IV study complemented this data and demonstrated restoration of sinus rhythm with vernakalant in 50.9% within 14 minutes. 16 The ACT II study focused on post-cardiac surgery patients -coronary artery bypass or valvular surgery -who developed AF for between 24 hours and 7 days. 13 Sinus rhythm was achieved in 47% versus 
Post-marketing Studies
Post-marketing studies have identified high cardioversion success rates. A real-world study included patients of AF onset ≤48 hours demonstrated 84.5% conversion to sinus rhythm with mean time to conversion 9 minutes and total hospital stay averaging 165 minutes. 21 The retrospective Malmö registry evaluated the median conversion time to be 11 minutes and 76% of patients converted to sinus rhythm when the AF duration was <10 hours compared to 66% when the AF was >10 hours. 22 Vernakalant was compared to electrical cardioversion in a retrospective study by Heikkola et al. 27 The vernakalant group (n=197) had lower numbers to successful conversion (66.5%) than the electrical cardioversion group (n=199; 94%). However, the vernakalant group were discharged sooner, with lower rates of AF recurrence at 1-year follow-up (36% versus 63%). 
AF or utter
• Dilute to a concentrate of 4 mg/ml (with 0.9% sodium chloride or 5% glucose) • Dose calculated according to weight:* ≤100 kg: 25 ml of vernakalant 20 mg/ml in 100 ml of diluent ≥100 kg: 30 ml of vernakalant 20 mg/ml in 120 ml of diluent • Recommended initial infusion: 3 mg/kg over 10 min 
Cost
Vernakalant is more expensive than other antiarrhythmic medicines, e.g. amiodarone and flecainide. 25 A costing analysis was undertaken by Vogiatzis et al. in their trial comparing vernakalant with ibutilide. 25 The ibutilide group were less likely to leave hospital at 2 hours and therefore incurred higher costs in terms of subsequent management and hospitalisation. While vernakalant is five to six times more expensive than ibutilide, the overall treatment costs were lower in the vernakalant group due to fewer adverse effects and shorter hospital stays. This is supported by the studies mentioned above, where more rapid discharge occurs due to successful early cardioversion with vernakalant, and it can be further supported by local audit data.
Local Use and Audit
In the British Isles, vernakalant was introduced in the Channel An on-going audit demonstrates an 87% success rate in the conversion from recent onset AF to sinus rhythm. There have been no serious untoward events, although a small number of patients have experienced sneezing as a side-effect. Vernakalant has mostly been used in the emergency department, although two patients were treated in the high dependency unit and later discharged home. Of the 87% who reverted to sinus rhythm, all were discharged home at 2 hours. The remaining patients were either discharged home in rate-controlled AF, with one patient admitted for overnight observation due to a slightly elevated heart rate in AF. All patients were seen at 4 weeks in the local arrhythmia clinic and at follow-up, 87% of patients remained in sinus rhythm with no AF recurrence.
Protocols and algorithms produced for the implementation of vernakalant have been shared with 10 centres in the UK, whom are making their own applications to obtain this novel antiarrhythmic.
Conclusion
Vernakalant offers a novel approach to pharmacological cardioversion.
Ease of administration and success rates for the conversion of recent onset AF encourage utilisation, particularly in the emergency department and acute care settings. The safety profile is reassuring as long as patients are selected appropriately. Post-marketing studies continue to be conducted with systematic reviews and meta-analysis published, demonstrating continued efficacy and overall effectiveness. 
Clinical Perspective
• AF is increasing in prevalence and is a frequent cause of hospital attendance.
• Vernakalant is an antiarrhythmic drug licensed for pharmacological cardioversion of recent onset AF.
• Vernakalant is administered via an IV infusion in a monitored, clinical environment and is safe and effective in the cardioversion of recent onset AF.
• Clinical trials and real-world data support international guidelines recommending vernakalant as a treatment of choice in selected patients with AF.
• When rhythm control is required, vernakalant offers a novel approach to facilitating rapid pharmacological conversion to sinus rhythm.
